Journal
CIRCULATION-GENOMIC AND PRECISION MEDICINE
Volume 12, Issue 4, Pages -Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCGEN.119.002470
Keywords
coronary artery disease; genetics; myocardial infarction; prognosis; secondary prevention
Funding
- British Heart Foundation Intermediate Fellowship [FS/14/76/30933]
- National Institute for Health Research University College London Hospitals Bio-medical Research Center
- UK Medical Research Council
- British Heart Foundation Intermediate Clinical Research Fellowship [FS/18/23/33512]
- National Institute for Health Research Oxford Biomedical Research Center
- Netherlands Heart Foundation [2001D019, 2003T302, 2007B202, CVON 2012-10]
- Leducq Foundation [05-CVD]
- Center for Translational Molecular Medicine (CTMM COHFAR)
- NIH [R0133169, R01ES021801, R01MD010358, R01ES025786, R01HL103866, R01DK106000, R01HL126827, P20HL113452, P01HL098055, P01HL076491, R01HL103931]
- National Institute for Health Research (NIHR)
- Barts Charity
- Aarno Koskelo Foundation
- Helsinki University Central Hospital special government funds [TYH7215, TKK2012005, TYH2012209, TYH2014312]
- Finnish Foundation for Cardiovascular research
- National Heart, Lung, and Blood Institute (NHLBI) [A. Fox/R01 HL 098601]
- Heart Foundation of New Zealand
- National Institutes of Health/National Institutes of Aging [AG051633]
- Abraham J. AMP
- Phyllis Katz Foundation (Atlanta, GA)
- National Institutes of Health (NIH) [5P01HL101398-02, 1P20HL113451-01, 1R56HL126558-01, 1RF-1AG051633-01, R01 NS064162-01, R01 HL89650-01, HL095479-01, 1U10HL110302-01, 1DP3DK094346-01, 2P01HL086773-06A1]
- EU [692145]
- Estonian Research Council [IUT20-60, IUT24-6, PUT1660, PUT735]
- European Union [01KL1802, 2014-2020.4.01.15-0012]
- ERA-CVD grant Detectin-HF [2R01DK075787-06A1]
- FAST-MI (French Registry of Acute ST-Elevation or non-ST-elevation Myocardial Infarction)
- Pfizer
- Servier
- French Caisse Nationale d'Assurance Maladie
- Nova Scotia, Ontario
- Quebec (HSFC)
- Wellcome Trust [072960/Z/03/Z, 084726/Z/08/Z, 084727/Z/08/Z, 085475/Z/08/Z, 085475/B/08/Z]
- EU IMI-SUMMIT programme
- NHS Education of Scotland/Chief Scientist Office Postdoctoral Clinical Lectureship [PCL 17/07]
- Italian Ministry of Research's Fund for Basic Research
- Sanofi Aventis
- Chief Scientist Office, Scotland
- National Institute of Health Pharmacogenomics Research Network grant [U01-GM074492, R01 HL074730]
- University of Florida Opportunity Fund
- BASF Pharma
- German Ministry of Education and Research [01GD9820/0, 01ER0814]
- Willy-Robert-Pitzer Foundation
- Waldburg-Zeil Clinics Isny
- Polish Ministry of Science and Higher Education [NN402083939]
- National Science Centre [2013/09/B/NZ5/00770]
- Leipzig Research Center for Civilization Diseases (LIFE)
- European Union
- European Regional Development Fund (ERDF)
- Free State of Saxony
- 7th Framework Program (AtheroRemo) of the European Union [201668, 305739]
- European Research Council
- Swedish Heart-Lung Foundation
- Swedish Research Council
- Crafoord Foundation
- Skane University Hospital in Lund
- Scania county
- Swedish Foundation for Strategic Research
- European Research Council Advanced Grant [294609]
- Italian Ministry of Health [PE-2013-02356818]
- Italian Ministry of Education, University and Research [2015583WMX]
- University of Ottawa Heart Institute
- Heart and Stroke Foundation
- Established Clinical Investigator of the Netherlands Heart Foundation [2001 D 032]
- European commission [223004]
- Netherlands Genomics Initiative (Netherlands Consortium for Healthy Aging) [050-060-810]
- FRSQ
- Merck Frost Canada
- Pfizer Canada
- Swedish Council for Work Life and Social Research
- Stockholm County Council
- Genome Canada
- Genome Quebec
- Canadian Institutes of Health Research (CIHR)
- Fonds de recherche du Quebec-Sante (FRQS)
- National Institutes of Health [Cresci R01 NR013396]
- National Institutes of Health: Washington University School of Medicine SCCOR [P50 HL077113]
- Dutch Top Institute Pharma Mondriaan Project
- Cariverona Foundation
- Veneto Region
- Italian Ministry of Education, University, and Research (MIUR)
- LURM (Laboratorio Universitario di Ricerca Medica) Research Center, University of Verona
- National Centre for Research and Development (NCBiR) [R13 0001 06]
- Medical University of Warsaw
- British Heart Foundation
- UCL Hospitals NIHR Biomedical Research Centre, EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking BigData@Heart grant [116074]
- European Union's Horizon 2020 research and innovation programme under the ERA-NET Co-fund action [01KL1802]
- BHF [PG/18/5033837]
- Health Research Council
- NIH-GIANT
- Canadian Institutes of Health Research
- Heart and Stroke Foundation of Alberta
- Heart and Stroke Foundation of NWT Nunavut
- Heart and Stroke Foundation of British Columbia
- Heart and Stroke Foundation of Yukon
- MH, Czech Republic [00023001]
- Wellcome Trust
- Abbott Laboratories
- Epidemiologia e Genetica della Morte Improvvisa in Sardegna
- Swedish National Health Service
- National Science Center (Poland) [402 529139]
- Bristol Myers Squibb
- HSFC
- Netherlands Heart Foundation
- European Research Council (ERC) [294609] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
BACKGROUND: The Genetics of Subsequent Coronary Heart Disease (GENIUS-CHD) consortium was established to facilitate discovery and validation of genetic variants and biomarkers for risk of subsequent CHD events, in individuals with established CHD. METHODS: The consortium currently includes 57 studies from 18 countries, recruiting 185 614 participants with either acute coronary syndrome, stable CHD, or a mixture of both at baseline. All studies collected biological samples and followed-up study participants prospectively for subsequent events. RESULTS: Enrollment into the individual studies took place between 1985 to present day with a duration of follow-up ranging from 9 months to 15 years. Within each study, participants with CHD are predominantly of self-reported European descent (38%-100%), mostly male (44%-91%) with mean ages at recruitment ranging from 40 to 75 years. Initial feasibility analyses, using a federated analysis approach, yielded expected associations between age (hazard ratio, 1.15; 95% CI, 1.14-1.16) per 5-year increase, male sex (hazard ratio, 1.17; 95% CI, 1.13-1.21) and smoking (hazard ratio, 1.43; 95% CI, 1.35-1.51) with risk of subsequent CHD death or myocardial infarction and differing associations with other individual and composite cardiovascular endpoints. CONCLUSIONS: GENIUS-CHD is a global collaboration seeking to elucidate genetic and nongenetic determinants of subsequent event risk in individuals with established CHD, to improve residual risk prediction and identify novel drug targets for secondary prevention. Initial analyses demonstrate the feasibility and reliability of a federated analysis approach. The consortium now plans to initiate and test novel hypotheses as well as supporting replication and validation analyses for other investigators.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available